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Clinical PerspectiveWhat Is New?This is the first study focus on the association of chest pain center accreditation with improved in‐hospital major adverse cardiovascular events of acute myocardial infarction patients in China based on a large‐scale national registry covering 15 344 patients from 40 hospitals.What are the Clinical Implications?This study demonstrated and confirmed the importance and effectiveness of chest pain center development and accreditation in China.Hazards for the risk of outcomes during the in‐hospital period as a function of the duration of accreditation followed a reverse J‐shaped trend, with the maximum associated effectiveness occurring up until the first year after accreditation, supporting the rationale of the recently established CPC reaccreditation project to ensure a long‐lasting effect after initial CPC accreditation.

Introduction {#jah34502-sec-0008}
============

Since 1981, when the concept of the chest pain center (CPC) was introduced, studies have shown that CPC is associated with improving timing of chest pain diagnosis, reperfusion time of ST‐segment--elevation myocardial infarction (STEMI) and reduced readmissions and costs.[1](#jah34502-bib-0001){ref-type="ref"}, [2](#jah34502-bib-0002){ref-type="ref"}, [3](#jah34502-bib-0003){ref-type="ref"}, [4](#jah34502-bib-0004){ref-type="ref"} Accreditation by the Society of Chest Pain Centers (now known as the American College of Cardiology \[ACC\] accreditation committee) has further standardized CPCs in the United States, and the ACC accreditation committee has promoted international accreditation standards since 2010.[5](#jah34502-bib-0005){ref-type="ref"}, [6](#jah34502-bib-0006){ref-type="ref"}, [7](#jah34502-bib-0007){ref-type="ref"} Several countries have also established their national CPC accreditation projects, such as the Chest Pain Unit Certification Working Group issued by the German Society of Cardiology.[8](#jah34502-bib-0008){ref-type="ref"}, [9](#jah34502-bib-0009){ref-type="ref"}, [10](#jah34502-bib-0010){ref-type="ref"}

The incidence and mortality of acute myocardial infarction (AMI) are increasing in China, and the in‐hospital mortality of STEMI patients has not improved over the past decade.[11](#jah34502-bib-0011){ref-type="ref"}, [12](#jah34502-bib-0012){ref-type="ref"}, [13](#jah34502-bib-0013){ref-type="ref"} The development of CPCs in China was initiated in 2010, and the headquarters of China Chest Pain Centers, which oversees CPC accreditation, was officially established in July 2016 to coordinate social resources and promote the rapid development of CPCs.[14](#jah34502-bib-0014){ref-type="ref"}, [15](#jah34502-bib-0015){ref-type="ref"} To date, evidence has not shown whether the outcomes of AMI patients are improved by CPC accreditation in China. The purpose of this study was to evaluate whether patients admitted for AMI after CPC accreditation had better in‐hospital outcomes than those admitted before accreditation and to further study the temporal associations of the accreditation process on AMI quality improvement.

Methods {#jah34502-sec-0009}
=======

For the concern about intellectual property and patient privacy, the data, analytic methods, and study materials will not be made available to other researchers for purposes of reproducing the results or replicating the procedure.

Study Design {#jah34502-sec-0010}
------------

The CCC‐ACS (Improving Care for Cardiovascular Disease in China--Acute Coronary Syndrome) project is a nationwide registry and quality improvement study with an ongoing database focusing on quality of acute coronary syndrome care. Details of the study design and methodology of the CCC‐ACS project have been described elsewhere.[16](#jah34502-bib-0016){ref-type="ref"} A standard procedure was used during data collecting from the patients' medical records, and third‐party research associates performed regular quality audits to ensure the accuracy and completeness of research data. Institutional review board approval was granted for this research by the ethics committee of Beijing Anzhen Hospital, Capital Medical University, and no informed consent was required.

Study Population {#jah34502-sec-0011}
----------------

From November 1, 2014, to June 30, 2017, a total of 63 641 patients diagnosed with acute coronary syndrome from 150 hospitals were registered in the database, among which 19 270 patients from 40 accredited hospitals during this period were included in this study. We excluded 2659 patients who were admitted to 10 hospitals with data only before or after accreditation and 1182 patients diagnosed with unstable angina pectoris. In addition, 85 patients with missing data about key variables for the identification of in‐hospital outcomes and candidate factors were excluded. Finally, 15 344 patients were included in the final analyses (Figure [1](#jah34502-fig-0001){ref-type="fig"}).

![Flow diagram of selection of the study population. CCC‐ACS indicates Improving Care for Cardiovascular Disease in China‐Acute Coronary Syndrome; UAP, unstable angina pectoris.](JAH3-8-e013384-g001){#jah34502-fig-0001}

In‐Hospital Outcomes {#jah34502-sec-0012}
--------------------

In this study, the primary outcome was major adverse cardiovascular events (MACE), including all‐cause death, reinfarction, stent thrombosis, stroke, and heart failure during hospitalization. The secondary outcome was in‐hospital all‐cause death. Only those incidents that occurred within 7 days of admission were taken into account for the analysis because the main effect of the CPC was reflected a short time after the first medical contact; there will be more censored data because of hospital discharge.

Statistical Analysis {#jah34502-sec-0013}
--------------------

Hospital information, demographic characteristics, medical history, clinical procedures, and 7‐day in‐hospital outcomes of the participants were compared by hospital status of accreditation (before and after) when each patient was admitted. Continuous variables were shown as mean±SD. Categorical variables were presented as the number (percentage). Differences in various characteristics among the groups were compared using the Student *t* test and χ^2^ test.

The differences of 7‐day in‐hospital outcomes between the 2 groups were compared in a propensity score--matched population to minimize selection bias from the real world. Patients admitted to hospitals before accreditation were matched at a 1:1 ratio with randomly selected patients admitted to hospitals after accreditation, on the basis of nearest neighbor in terms of Mahalanobis distance with a caliper of 0.02. Propensity score was estimated with a logistic regression model with the variables of age; sex; hospital location (first‐line municipality, provincial capital, or prefecture‐level city); first medical contact site (no or yes); department arrived (emergency and catheter lab, or outpatient and others); comorbidities including smoking status, diabetes mellitus, hypertension, and dyslipidemia; heart failure history; renal failure history; previous myocardial infarction (MI); previous percutaneous coronary intervention or coronary artery bypass grafting; type of MI; Killip classes; preadmission use of aspirin; preadmission use of P2Y~12~ receptor inhibitors; and preadmission use of statins.

The incidence of 7‐day in‐hospital outcomes by hospital status of accreditation in the whole study population and in the propensity score--matched subset were compared. Because some variables were not comparable between the 2 groups even after propensity score matching, we used mixed‐effects Cox proportional hazards models containing Gaussian random effects, also known as frailty models, to compare the risk by adjusting other confounders in the logistic regression model, considering that this data set contained hospital‐level information and the data structure was hierarchical.

Subgroup analyses of 7‐day in‐hospital outcomes were then performed according to important characteristics, including age (\<65 or ≥65 years), sex (male or female), city type (provincial capital or prefecture‐level city), first medical contact site (no or yes), department arrived (emergency and catheter lab, or outpatient and others), type of MI (STEMI or non‐STEMI), Killip class I (no or yes), previous MI (no or yes), and previous percutaneous coronary intervention or coronary artery bypass grafting (no or yes).

Considering the quality improvement effect of the CCC‐ACS project itself along with time, we performed sensitivity analyses in patients admitted to hospitals without accreditations during the project and those contemporarily admitted in hospitals after accreditation. Propensity score was also estimated with a logistic regression model with all of the listed variables included plus the admission date. Cox proportional hazards models were then used to compare the risk of 7‐day in‐hospital outcomes.

A 2‐tailed *P*\<0.05 was considered statistically significant in all analyses. R software (<http://www.R-project.org>) was used for all statistical analyses.

Results {#jah34502-sec-0014}
=======

Patient Characteristics {#jah34502-sec-0015}
-----------------------

A total of 15 344 patients were enrolled in this study from 40 hospitals, including 7544 admitted before the accreditation and 7800 after accreditation. Baseline characteristics are shown in Table [1](#jah34502-tbl-0001){ref-type="table"}. Compared with patients admitted to hospitals when not accredited, those admitted after accreditation were mainly from hospitals in cities of provincial capitals, had the hospital as the first medical facility, and arrived in the emergency department and catheter lab. The postaccreditation group had more patients diagnosed with STEMI and had a higher proportion of patients with Killip class I. Comparing comorbidities, patients in the postaccreditation group were less likely to have hypertension, dyslipidemia, heart failure history, and previous MI but more likely to have previous percutaneous coronary intervention or coronary artery bypass grafting. In addition, there were fewer patients to be treated with statins in the postaccreditation group regarding preadmission medications.

###### 

Baseline Characteristics of the Study Population

  Variable                                Unmatched       Propensity Score Matched                                             
  --------------------------------------- --------------- -------------------------- --------- --------------- --------------- -------
  n                                       7544            7800                                 6700            6700            
  Age, y                                  62.48 (12.61)   62.52 (12.52)              0.838     62.36 (12.62)   62.42 (12.67)   0.782
  Female sex                              1796 (23.8)     1808 (23.2)                0.369     1564 (23.3)     1566 (23.4)     0.984
  Hospital location: provincial capital   4554 (60.4)     5122 (65.7)                \<0.001   4240 (63.3)     4301 (64.2)     0.281
  First medical facility: hospital        3712 (49.2)     4124 (52.9)                \<0.001   3367 (50.3)     3366 (50.2)     1.000
  Department: Emergency/catheter lab      5278 (70.0)     6046 (77.5)                \<0.001   5025 (75.0)     4995 (74.6)     0.564
  Type of MI                                                                                                                   
  STEMI                                   5296 (70.2)     5659 (72.6)                0.001     4824 (72.0)     4831 (72.1)     0.908
  Killip class                                                                                                                 
  I                                       5298 (70.2)     5797 (74.3)                \<0.001   4835 (72.2)     4879 (72.8)     0.651
  II to III                               1966 (26.1)     1735 (22.2)                          1624 (24.2)     1593 (23.8)     
  IV                                      280 (3.7)       268 (3.4)                            241 (3.6)       228 (3.4)       
  Comorbidity                                                                                                                  
  Current smoking                         3577 (47.4)     3760 (48.2)                0.335     3213 (48.0)     3198 (47.7)     0.809
  Hypertension                            4052 (53.7)     3992 (51.2)                0.002     3534 (52.7)     3389 (50.6)     0.013
  Dyslipidemia                            543 (7.2)       358 (4.6)                  \<0.001   344 (5.1)       352 (5.3)       0.785
  Diabetes mellitus                       1694 (22.5)     1733 (22.2)                0.739     1477 (22.0)     1500 (22.4)     0.648
  Heart failure history                   120 (1.6)       71 (0.9)                   \<0.001   65 (1.0)        69 (1.0)        0.795
  Renal failure history                   84 (1.1)        85 (1.1)                   0.949     74 (1.1)        70 (1.0)        0.802
  Previous MI                             575 (7.6)       453 (5.8)                  \<0.001   395 (5.9)       412 (6.1)       0.561
  Previous PCI or CABG                    446 (5.9)       519 (6.7)                  0.063     391 (5.8)       412 (6.1)       0.467
  Preadmission medication                                                                                                      
  Aspirin                                 1288 (17.1)     1259 (16.1)                0.126     1081 (16.1)     1104 (16.5)     0.607
  P2Y~12~ receptor inhibitors             935 (12.4)      929 (11.9)                 0.372     794 (11.9)      820 (12.2)      0.507
  Statins                                 908 (12.0)      815 (10.4)                 0.002     714 (10.7)      738 (11.0)      0.523

Data are expressed as mean±SD or n (%). CABG indicates coronary artery bypass grafting; MI, myocardial infarction; PCI, percutaneous coronary intervention; STEMI, ST‐segment--elevation myocardial infarction.

After propensity score matching, postmatching absolute standardized differences were \<10% for all covariates. The mirrored histograms before and after matching are shown in Figure [S1](#jah34502-sup-0001){ref-type="supplementary-material"} to present the propensity score distribution status. A total of 6700 patients in each group were matched. The characteristics of the 2 groups were recompared. In the propensity score--matched population, there were no significant differences of baseline characteristics between the 2 groups except for hypertension comorbidity (Table [1](#jah34502-tbl-0001){ref-type="table"}).

Seven‐Day In‐Hospital Outcomes {#jah34502-sec-0016}
------------------------------

In‐hospital outcomes within 7 days of admission were compared according to accreditation status (Table [2](#jah34502-tbl-0002){ref-type="table"}). In the whole study population, the incidence of MACE was significantly lower in patients admitted after accreditation compared with those admitted before accreditation (6.4% versus 8.4%; *P*\<0.001), mainly due to heart failure. The incidence of all‐cause death was also significantly lower after versus before accreditation (1.1% versus 1.6%; *P*=0.016). Cumulative hazards of MACE and all‐cause death were also lower in the postaccreditation group compared with the preaccreditation group (log rank *P*\<0.001 and *P*=0.020, respectively; Figure [2](#jah34502-fig-0002){ref-type="fig"}A and [2](#jah34502-fig-0002){ref-type="fig"}C).

###### 

In‐Hospital Outcomes Within 7 Days After Hospitalization[a](#jah34502-note-0006){ref-type="fn"}

  Variable                  Unmatched   Propensity Score Matched                                     
  ------------------------- ----------- -------------------------- --------- ----------- ----------- -------
  n                         7544        7800                                 6700        6700        
  MACE, n (%)               636 (8.4)   498 (6.4)                  \<0.001   539 (8.0)   448 (6.7)   0.003
  All‐cause death, n (%)    120 (1.6)   88 (1.1)                   0.016     107 (1.6)   75 (1.1)    0.021
  Cardiac death, n (%)      114 (1.5)   85 (1.1)                   0.025     101 (1.5)   72 (1.1)    0.032
  Reinfarction, n (%)       18 (0.2)    11 (0.1)                   0.228     14 (0.2)    10 (0.1)    0.540
  Stent thrombosis, n (%)   10 (0.1)    7 (0.1)                    0.579     9 (0.1)     7 (0.1)     0.802
  Stroke, n (%)             12 (0.2)    8 (0.1)                    0.456     11 (0.2)    7 (0.1)     0.479
  Heart failure, n (%)      547 (7.3)   419 (5.4)                  \<0.001   459 (6.9)   378 (5.6)   0.004

Data are expressed as n (%). MACE indicates major adverse cardiovascular events.

Patients may have had \>1 outcome in each category but were counted only once for overall events.

![Cumulative Kaplan--Meier curve estimates of outcomes within 7 days after hospitalization. Data for MACE in the whole study population (**A**) and the propensity score--matched population (**B**). Data for all‐cause death in the whole study population (**C**) and the propensity score‐matched population (**D**). HR indicates hazard ratio; MACE, major adverse cardiovascular events.](JAH3-8-e013384-g002){#jah34502-fig-0002}

After propensity score matching, the incidence of 7‐day in‐hospital MACE (6.7% versus 8.0%; *P*=0.003) and all‐cause death (1.1% versus 1.6%; *P*=0.021) was still lower in the postaccreditation group (log rank *P*=0.003 and *P*=0.020, respectively; Table [2](#jah34502-tbl-0002){ref-type="table"}, Figure [2](#jah34502-fig-0002){ref-type="fig"}B and [2](#jah34502-fig-0002){ref-type="fig"}D).

In mixed‐effects Cox proportional hazards models, CPC accreditation was associated with statistically significantly decreased risk of MACE (hazard ratio \[HR\]: 0.78; 95% CI, 0.68--0.91; *P*=0.001) and all‐cause death (HR: 0.71; 95% CI, 0.51--0.99; *P*=0.042) after multivariate analysis adjusted for possible confounders (Table [3](#jah34502-tbl-0003){ref-type="table"}).

###### 

Outcomes Within 7 Days After Hospitalization Associated With Accreditation: Unadjusted and Multivariate Adjusted Analyses With and Without Propensity Score Matching

  Variable                                                                   Unmatched   Propensity Score Matched          
  -------------------------------------------------------------------------- ----------- -------------------------- ------ -------------------
  MACE                                                                                                                     
  Crude HR (95% CI)                                                          1.00        0.79 (0.68--0.9)           1.00   0.85 (0.74--0.98)
  *P* value                                                                              0.001                             0.029
  Age‐ and sex‐adjusted HR (95% CI)                                          1.00        0.75 (0.65--0.86)          1.00   0.81 (0.7--0.94)
  *P* value                                                                              \<0.001                           0.006
  Multivariate adjusted HR (95% CI)[a](#jah34502-note-0008){ref-type="fn"}   1.00        0.77 (0.67--0.88)          1.00   0.78 (0.68--0.91)
  *P* value                                                                              \<0.001                           0.001
  All‐cause death                                                                                                          
  Crude HR (95% CI)                                                          1.00        0.67 (0.49--0.91)          1.00   0.67 (0.48--0.93)
  *P* value                                                                              0.011                             0.017
  Age‐ and sex‐adjusted HR (95% CI)                                          1.00        0.64 (0.47--0.88)          1.00   0.64 (0.46--0.89)
  *P* value                                                                              0.005                             0.009
  Multivariate‐adjusted HR (95% CI)[a](#jah34502-note-0008){ref-type="fn"}   1.00        0.69 (0.5--0.95)           1.00   0.71 (0.51--0.99)
  *P* value                                                                              0.022                             0.042

HR indicates hazard ratio; MACE, major adverse cardiovascular events; MI, myocardial infarction.

Adjusted for age, sex, the level of the city where the hospital is located, first medical contact site or not, comorbidities including smoking status, diabetes mellitus, hypertension, dyslipidemia, diabetes mellitus, heart failure history, renal failure history, previous MI, previous percutaneous coronary intervention or coronary artery bypass grafting, type of MI, Killip classes, preadmission use of aspirin, preadmission use of P2Y~12~ receptor inhibitors, and preadmission use of statins.

Hazards for the risk of outcomes during the in‐hospital period by the duration of accreditation in the propensity score--matched population are presented in Figure [3](#jah34502-fig-0003){ref-type="fig"}. The risk of MACE and all‐cause death for those patients admitted after the accreditation both follow a reverse J‐shaped trend: the risk of both MACE and all‐cause death decreases gradually with CPC accreditation, with the minimal risk occurring in patients admitted from 6 months to the first year after accreditation, and then risk increases in the second year and after.

![Hazard for the risk of outcomes within 7 days after hospitalization by the duration of accreditation. Data for MACE in the whole study population (**A**) and the propensity score--matched population (**B**). Data for all‐cause death in the whole study population (**C**) and the propensity score--matched population (**D**). MACE indicates major adverse cardiovascular events.](JAH3-8-e013384-g003){#jah34502-fig-0003}

Subgroup Analyses {#jah34502-sec-0017}
-----------------

Subgroup analyses for MACE and all‐cause death based on baseline information were performed in the propensity score--matched population (Figures [S2 and S3](#jah34502-sup-0001){ref-type="supplementary-material"}). The main results were not significantly changed in most subgroups. No interactions were found in most subgroups except for MACE risk by the type of MI (*P*=0.002 for interaction) and the disease history of previous percutaneous coronary intervention or coronary artery bypass grafting (*P*=0.049 for interaction); the associated risk of MACE was decreased more significantly after CPC accreditation in patients diagnosed with STEMI (HR: 0.70; 95% CI, 0.58--0.84) compared with those diagnosed with non‐STEMI (HR: 0.97; 95% CI, 0.75--1.26).

Sensitivity Analyses {#jah34502-sec-0018}
--------------------

Sensitivity analyses included 36 911 patients admitted to hospitals without accreditations during the project and 8858 patients contemporarily admitted in hospitals after accreditation (Figure [S4](#jah34502-sup-0001){ref-type="supplementary-material"}). After propensity score matching at a 1:1 ratio, postmatching absolute standardized differences were \<10% for all covariates except for admission date. The mirrored histograms are shown in Figure [S5](#jah34502-sup-0001){ref-type="supplementary-material"} to present the propensity score distribution status.

Baseline characteristics between no accreditation and postaccreditation groups before propensity score matching were not significantly different from the main results except those regarding hospital location, type of MI, and history of diabetes mellitus (Table [S1](#jah34502-sup-0001){ref-type="supplementary-material"}). The results for the risk of in‐hospital outcomes within 7 days after admission did not significantly change except for the comparison of all‐cause death, with a *P* value not significantly different (Tables [S2 and S3](#jah34502-sup-0001){ref-type="supplementary-material"}; Figure S6).

Discussion {#jah34502-sec-0019}
==========

Our study found that AMI patients admitted to hospitals with CPC accreditation had better in‐hospital outcomes than those admitted to hospitals without accreditation, based on a large‐scale national registry data set, even after propensity score matching and using Cox proportional hazards models. To our knowledge, this study is the first to focus on this issue in China. This is especially important because a previous study found no improvement of outcome for STEMI patients from 2001 to 2011.[11](#jah34502-bib-0011){ref-type="ref"} The results of this study confirm the importance and effectiveness of CPC development and accreditation for AMI patients in China.

The most compelling reason for hospitals and programs to obtain accreditations is better patient outcomes, but prior studies focusing on the impact of accreditation were inconclusive. A recent study including \>4 million patients aged ≥65 years showed no patient mortality benefit for hospitals with a Joint Commission certification compared with those accredited by another independent accrediting organization.[17](#jah34502-bib-0017){ref-type="ref"} Another recent analysis showed that there might be differences in treatment and mortality for stroke patients according to which organization provided certification.[18](#jah34502-bib-0018){ref-type="ref"} However, regarding AMI patients, previous studies have shown that CPC accreditation was associated with better performance on core measurements,[19](#jah34502-bib-0019){ref-type="ref"} which is the fundamental goal for CPC accreditation.[20](#jah34502-bib-0020){ref-type="ref"}, [21](#jah34502-bib-0021){ref-type="ref"}, [22](#jah34502-bib-0022){ref-type="ref"}, [23](#jah34502-bib-0023){ref-type="ref"} These findings suggested that the improvements in care processes with CPC accreditation are further associated with improved short‐term outcomes for AMI patients.

Our study found that CPC accreditation was associated with statistically significant risk reduction of MACE and all‐cause death after adjustment. Although the main contributor to MACE improvement was heart failure, all‐cause mortality was also significantly improved with CPC accreditation, even in Cox proportional hazards models, which means the conclusion was solid. Although the history of CPC accreditation in China is relatively short, this study suggested that there were favorable associations with clinical outcomes. Further implementation and optimization of accreditation standards, focused especially on core measurements for care management of AMI patients, may be warranted.

In 2010, the China Expert Consensus on the Construction of Chest Pain Centers was published and played a crucial role in promoting the development of CPCs at that time.[15](#jah34502-bib-0015){ref-type="ref"} The first CPC in China with the regional collaborative network as its core concept was established in March 2011 in Guangzhou. With the scope of collaboration with resources and promoting the rapid development of CPCs, the China Cardiovascular Association and the Chinese Society of Cardiology collaboratively established the China Chest Pain Center in July 2016. After its establishment, this CPC assumed responsibility for most of the organization, management, and coordination originally undertaken by the China Chest Pain Center Accreditation Office. More details on the process, benchmarks, requirements, and so forth, according to CPC certification in China are provided in Data [S1](#jah34502-sup-0001){ref-type="supplementary-material"} for reference.

An important insight from this study is that the hazards for the risk of outcomes during the in‐hospital period as a function of the duration of accreditation followed a reverse J‐shaped trend, with the maximum associated effectiveness occurring up until the first year after accreditation. This finding supports the rationale of the recently established reaccreditation project, which may promote a long‐lasting effect after initial CPC accreditation and help to limit subsequent declines in associated benefits for AMI care and outcomes with CPC accreditation after the first year. In January 2018, considering continuing quality improvement, the headquarters of China CPCs formally established a reaccreditation protocol and standard that demands a 3‐year validation period for the initial CPC accreditation. The validation period for the reaccreditation of CPCs will be 5 years, and reaccreditation should be performed every 5 years.

This study had several limitations. First, this was a retrospective observational study; even using propensity score matching, we could not eliminate bias from unobserved variables. A follow‐up study with a more robust design, such as prospective cluster randomization, would be warranted. Second, the difference in outcomes was largely driven by difference in heart failure and all‐cause death, which should be taken into consideration in the interpretation of results. Third, hospitals involved in CCC‐ACS projects cannot reflect the whole picture of China\'s hospitals with and without CPC accreditation; furthermore, this study focuses on only AMI rather than all acute chest pain diagnoses and diseases. Last, our analysis was able to focus on only in‐hospital outcomes rather than effect of accreditation on long‐term outcome improvements, which can be further studied in the future.

Conclusions {#jah34502-sec-0020}
===========

Based on a large‐scale national registry data set, CPC accreditation was associated with better in‐hospital outcomes for AMI patients. However, because there was some attenuation in associated benefits over time, reaccreditation may be essential to maintain the quality of AMI care after initial CPC accreditation.

Sources of Funding {#jah34502-sec-0022}
==================

The CCC‐ACS (Improving Care for Cardiovascular Disease in China‐Acute Coronary Syndrome) project is a collaborative program of the American Heart Association (AHA) and Chinese Society of Cardiology. The AHA was funded by Pfizer for the quality‐improvement initiative through an independent grant for learning and change.
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**Appendix S1.** Group information: hospitals for phase 1 (investigator).

**Data S1.** Details on the process, benchmarks, and requirements for chest pain center accreditation in China

**Table S1.** Baseline Characteristics of the Study Population in Sensitivity Analyses

**Table S2.** In‐Hospital Outcomes Within 7 Days After Hospitalization\* in Sensitivity Analyses

**Table S3.** Independent Predictors of Major Adverse Cardiovascular Events in Propensity Score--Matched Population in Sensitivity Analyses

**Figure S1.** Mirrored histogram before (**A**) and after (**B**) propensity score matching. The *x*‐axis shows the number of patients in each group. The *y*‐axis shows the propensity score. The red bar presents the preaccreditation group, and the blue bar shows the postaccreditation group.

**Figure S2.** Subgroup analyses for MACE in the propensity score--matched population. CABG indicates coronary artery bypass grafting; cath, catheter; HR, hazard ratio; MACE, major adverse cardiovascular events; MI, myocardial infarction; NSTEMI, non--ST‐segment--elevation myocardial infarction; PCI, percutaneous coronary intervention; STEMI, ST‐segment--elevation myocardial infarction.

**Figure S3.** Subgroup analyses for all‐cause death in the propensity score--matched population. CABG indicates coronary artery bypass grafting; cath, catheter; HR, hazard ratio; MACE, major adverse cardiovascular events; MI, myocardial infarction; NSTEMI, non--ST‐segment--elevation myocardial infarction; PCI, percutaneous coronary intervention; STEMI, ST‐segment--elevation myocardial infarction.

**Figure S4.** Flow diagram of selection of the study population in sensitivity analyses. CCC‐ACS indicates Improving Care for Cardiovascular Disease in China‐Acute Coronary Syndrome; UAP, unstable angina pectoris.

**Figure S5.** Mirrored histogram before (**A**) and after (**B**) propensity score matching in sensitivity analyses. The *x*‐axis shows the number of patients in each group. The *y*‐axis shows the propensity score. The red bar presents the no‐accreditation group, and the blue bar shows the postaccreditation group.

**Figure S6.** Cumulative Kaplan--Meier curve estimates of outcomes within 7 days after hospitalization in sensitivity analyses. Data for MACE in the whole study population (**A**) and the propensity score--matched population (**B**). Data for all‐cause death in the whole study population (**C**) and the propensity score--matched population (**D**). HR indicates hazard ratio; MACE, major adverse cardiovascular events.
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